Compare Kaltura Inc (KLTR) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kaltura Inc vs Merck & Co., Inc. — how do they compare? Kaltura Inc trades at $1.31 (market cap $199.08M), while Merck & Co., Inc. trades at $146.38 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 1764.5× Kaltura Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Kaltura Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kaltura Inc for 21 Days and Merck & Co., Inc. for 98 Days on average.
| KLTR | MRK | |
|---|---|---|
Market Cap | $199.08M | $351.28B |
Volume | 175,927 | 7,969,665 |
Sector | Technology | Health |
52-Week High | $1.89 | $156.43 |
52-Week Low | $1.08 | $82.49 |
Typical Hold Time | 21 Days | 98 Days |
Enterprise Value | $211.29M | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kaltura (KLTR) trades at $1.305, down 1.88% today, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with revenue stabilizing around $181M and net losses narrowing from -$68M in 2022 to -$12M in 2025. Recent positive developments include AI platform awards and major streaming deployments, though valuation metrics remain elevated with P/S of 1.08 and EV/EBITDA of 271.59.
The stock presents a turnaround story with improving profitability trends but faces significant execution risks. Analyst sentiment is mixed with 44% buy ratings, while technical indicators suggest near-term pressure. Key catalysts include AI product commercialization and further margin improvement, but high debt levels and persistent losses require careful monitoring.
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
